Innovative antirheumatic drugs and infections: Problems and solutions
Meditsinskiy sovet = Medical Council · 19.04.2026 · (3) · 164-174
DOI: 10.21518/ms2026-070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 19.04.2026. Verfasst von B. S. Belov und 2 weiteren Autor:innen. Die Arbeit nennt 82 Literaturangaben.
Abstract (Originalsprache)
In recent decades, there has been clear progress in rheumatology related to the introduction of genetically engineered biological disease-modifying antirheumatic drugs (bDMARDs) and targeted disease-modifying antirheumatic drugs (tDMARDs) into practice. At the same time, the use of these drugs is associated with an increasing risk of developing infections of a diverse nature and localization, including opportunistic ones, as well as an increased risk of reactivation of latent infection, primarily tuberculosis (TB). In addition, cases of severe infections (pneumonia, sepsis, bacterial arthritis, skin and soft tissue lesions, etc.), including fatal ones, have been reported. To date, the mechanisms underlying the increasing risk of infectious complications associated with the use of b/tDMARDs have not been fully recognized. Within the framework of this narrative (non-systematic) review, modern data on the frequency and localization of major infections in rheumatological patients treated with various b/tDMARDs are presented. The need for wider use of immunization with various vaccines (primarily against influenza and pneumococcal infection) in patients with immuno-inflammatory rheumatic diseases is emphasized. In preparing the review, the authors conducted an exhaustive literature search (mainly in English) in MEDLINE databases (via PubMed) for the following keywords: “biologics/rheumatic diseases AND infection”, “tumor necrosis factor-α antagonists/rheumatic diseases AND infection”, “targeted synthetic disease modifying antirheumatic drugs/rheumatic diseases AND infection” with preferential selection of national and international registers, systematic reviews and meta-analyses. The materials of two major annual international rheumatological forums held under the auspices of the European Alliance of Rheumatology Associations (EULAR) and the American College of Rheumatology (ACR) were also reviewed. After eliminating duplicate materials, 168 relevant sources were selected for further analysis.
Zitieren
APA
Belov, B. S., Muravieva, N. V., & Baranova, M. M. (2026). Innovative antirheumatic drugs and infections: Problems and solutions. Meditsinskiy sovet = Medical Council, 164-174. https://doi.org/10.21518/ms2026-070
Vancouver
Belov BS, Muravieva NV, Baranova MM. Innovative antirheumatic drugs and infections: Problems and solutions. Meditsinskiy sovet = Medical Council. 2026:164-174. doi:10.21518/ms2026-070
BibTeX
@article{Belov2026,
author = {Belov, B. S. and Muravieva, N. V. and Baranova, M. M.},
title = {Innovative antirheumatic drugs and infections: Problems and solutions},
journal = {Meditsinskiy sovet = Medical Council},
year = {2026},
number = {3},
pages = {164--174},
doi = {10.21518/ms2026-070}
}
EUVIMED